Novo Nordisk A/S (OCSE:NOVO B)
kr 936.2 12.3 (1.33%) Market Cap: 4.17 Til Enterprise Value: 4.19 Til PE Ratio: 47.03 PB Ratio: 42.23 GF Score: 93/100

Q1 2019 Novo Nordisk A/S Earnings Call Transcript

May 03, 2019 / 11:00AM GMT
Release Date Price: kr158.68 (-2.97%)
Operator

Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to today's Q1 2019 Novo Nordisk A/S Earnings Conference Call. (Operator Instructions) I must advise you, the conference today has been recorded on Friday, the 3rd of May 2019.

Without any further delay, I would like to hand the conference over to your first speaker today, Lars Fruergaard Jørgensen. Please go ahead, sir.

Lars Fruergaard JÃ;rgensen;S;President;CEO
Novo Nordisk A

¸ - /-&

Thank you very much. Welcome to this Novo Nordisk conference call regarding our performance in the first 3 Months of 2019 and our outlook for the year. I'm Lars Fruergaard Jørgensen, the CEO of Novo Nordisk. With me, I have our Chief Financial Officer, Karsten Munk Knudsen; and our Chief Science Officer, Mads Krogsgaard Thomsen. Also present and available for the Q&A session are Executive Vice President and Head of Commercial Strategy and Corporate Affairs, Camilla Sylvest; and Executive Vice President and Head of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot